IP Library Granted Patent US 8,216,172
Granted Patent B2
US 8,216,172 · App. 13/287,683 · Granted Jul 10, 2012

Method of performing hemofiltration

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,216,172
App. No.
13/287,683
Granted
Jul 10, 2012
Kind
B2
Abstract

A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Claims (13)

1. A method of performing hemofiltration, the method comprising:

extracting blood from a patient;

passing the blood through an artificial kidney having a semi-permeable membrane, wherein the blood is filtered over a semi-permeable membrane;

infusing a sterile, two part aqueous substitution infusion fluid into the filtered blood, wherein the sterile, two part aqueous substitution infusion fluid comprises a first aqueous substitution infusion fluid comprising sodium ions, potassium ions and phosphate ions and excluding calcium ions and magnesium ions, and a second aqueous substitution infusion fluid comprising calcium ions and magnesium ions; and

returning the infused blood to the patient.

2. The method of claim 1 , wherein the first aqueous substitution infusion fluid and the second aqueous substitution infusion fluid comprise sodium ions.

3. The method of claim 1 , wherein the second aqueous substitution infusion fluid comprises from about 70 mmol/L to about 130 mmol/L of sodium ion.

4. The method of claim 1 , wherein the second aqueous substitution infusion fluid comprises from about 0.01 mmol/L to about 5 mmol/L of potassium ion.

5. The method of claim 1 , wherein the second aqueous substitution infusion fluid comprises from about 100 mmol/L to about 150 mmol/L of chloride ion.

6. The method of claim 1 , wherein the first aqueous substitution infusion fluid comprises from about 0.01 mmol/L to about 1.5 mmol/L of the phosphate ion.

7. The method of claim 1 , wherein the second aqueous substitution infusion fluid comprises from about 2 mmo/n to about 11.5 mmol/L of glucose.

8. The method of claim 1 , wherein the first aqueous substitution infusion fluid comprises from about 0.01 mmol/L of potassium ion to about 5 mmol/L of potassium ion, from about 100 mmol/L to about 150 mmol/L of chloride ion, and from about 0.01 mmol/L to about 1.5 mmol/L of phosphate ion, and wherein the second aqueous substitution infusion fluid comprises from about 10 mmol/L to about 35 mmol/L of calcium ion and from about 2.5 mmol/L to about 20 mmol/L of magnesium ion.

9. The method of claim 1 , wherein a mixed first aqueous substitution infusion fluid and second aqueous substitution infusion fluid excludes acetate.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2014
From: BAXTER HEALTHCARE SA; BAXTER INTERNATIONAL INC.
To: NIKKISO CO., LTD.
Reel/Frame 032210/0629 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2012
From: EDWARDS LIFESCIENCES CORPORATION
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 027741/0996 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2012
From: CHANG, PETER C., DR.
To: EDWARDS LIFESCIENCES AG
Reel/Frame 027742/0001 →
CHANGE OF CORPORATE ADDRESS Recorded Feb 22, 2012
From: BAXTER HEALTHCARE S.A.
To: BAXTER HEALTHCARE S.A.
Reel/Frame 027747/0135 →